Why the study?
Does sitagliptin improve diabetic cardiomyopathy in experimental diabetic rats?
Population
Experimental diabetic rats (diabetes induced by streptozotocin injection)
Comparison
Sitagliptin administered orally and daily for 90… vs Untreated diabetic rats
Design
Preclinical
Follow-up
90 days
Authors
Loading...
Hypothesis-generating for sitagliptin in diabetic cardiomyopathy; prospective human trials needed before clinical adoption.
Does sitagliptin improve diabetic cardiomyopathy in experimental diabetic rats?
Sitagliptin attenuates diabetic cardiomyopathy in a rat model by down-regulating the JAK/STAT signaling pathway.
Mahmoud et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: